Loncastuximab

Details of the Drug

Generic Name:: Loncastuximab tesirine-lpyl
Drug Type:: CD19-directed antibody and alkylating agent conjugate
How the Drug is Given:: Intravenously (IV)
Names:: Zynlonta™; Loncastuximab tesirine-lpyl

Indications and Usage

Loncastuximab tesirine-lpyl is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Side effects needing medical attention

Most common adverse reactions are thrombocytopenia (low number of platelets), increased gamma-glutamyltransferase (the increase of an enzyme found mostly in the liver), neutropenia (low count of neutrophils), anemia (low number of red blood cells), hyperglycemia (high blood sugar levels), transaminase elevation, fatigue, hypoalbuminemia (low levels of albumin in the blood), rash, edema (swelling caused by fluid trapped in the body’s tissues), nausea, and musculoskeletal pain.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.